ABSTRACT

Introduction Intracerebral haemorrhage (ICH) is a life-threatening condition with no effective internal treatment options. However, edaravone is a promising therapeutic agent, although its beneficial effects are inconclusive based on previous systematic reviews and meta-analyses. While several trials in the last 8 years have reported the favourable long-term functional outcomes, a few reports indicated edaravone to be associated with an increase in adverse events.

Methods and analysis This protocol was performed in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols. We will perform the comprehensive and manual search for published articles, ongoing trials, dissertations and grey literature. The following databases will be searched from inception to 23 April 2020: Medline, Embase, the Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure, Chinese scientific periodical database of VIP INFORMATION, Wanfang Data and SinoMed, with no language restrictions. All randomised controlled trials that (1) compared edaravone with placebo or no treatment, and (2) compared edaravone plus routine treatment or co-intervention with routine treatment or co-intervention for treating acute ICH will be included. Mortality and long-term dependency will be the primary outcomes. The incidence of adverse events will be assessed for safety evaluation. Two reviewers in pairs will independently carry out the article selection, data extraction and quality assessment. Assessment of the risk of bias and data synthesis will be performed using software Review Manager V.5.3. Finally, we will use the Grading of Recommendations Assessment, Development and Evaluation approach to evaluate the quality of the overall evidence.

Ethics and dissemination There are no ethical considerations associated with this updated systematic review and meta-analysis. The findings will be disseminated in peer-reviewed journals or conference presentations.

PROSPERO registration number CRD42019147801.

INTRODUCTION

Non-traumatic intracerebral haemorrhage (ICH) is the second most common type of stroke, affecting 18.8%–47.6% of individuals across different races. It is usually caused by the rupture of small penetrating arteries leading to cerebral parenchymal bleeding which can extend into the ventricular, even subarachnoid space. Though survived, patients would suffer from various degrees of disability and other neurological complications additionally. Although important advances have been made in the areas of basic and clinical research, there are still no recommended effective internal medical treatments for ICH. Neuroprotection...
of the surrounding brain tissue from the degenerative effects of the haematoma is a suggested approach, which is yet to be validated.

Pathological mechanisms underlying ICH are commonly categorised into (1) primary injury which refers to a direct injury caused by mass effect of the haematoma or by neurovascular disruption, and (2) secondary injury that involves in the cascade events triggered by the primary injury and its metabolites. The coagulation cascade (especially thrombin), haemoglobin breakdown products, inflammation and free radicals all contributed to ICH-induced injury. Free radical-induced damage is considered to be particularly deleterious, and clinical trials have assessed the potential of free radical scavengers to ameliorate the damage.

Edaravone (MCI-186, 3-methyl-1-phenyl-2-pyrazolin-5-one) is a potent free radical scavenger that was initially approved for treating acute ischaemic stroke (AIS) in Japan. Based on the similar pathological process of AIS and ICH, edaravone was tested in ICH models. It was shown to improve the neurological deficits in ICH models via anti-inflammatory and antiapoptotic mechanisms, attenuating the ICH-induced brain oedema and oxidative injury, as well as reducing iron-induced and thrombin-induced brain injury. Additionally, edaravone is reported to demonstrate obvious neuroprotective effects in patients with ICH and has been widely used in clinic. Considering the differences in the pathology of ICH and AIS, it is important to evaluate the specifics of edaravone therapy for ICH, which include the right time to start treatment, optimal dose and duration of treatment. Basic studies have shown that with AIS, treatment of ICH requires higher doses of edaravone, indicating its dose-dependent neuroprotective effects. However, the dose of edaravone for ICH treatment in previous systematic review and meta-analysis was similar to that for AIS. Moreover, these previous studies only showed edaravone alleviating neurological function deficits, while its effect on survival or dependency at the end of long-term follow-up was not reported. Over the past 8 years, emerging evidence from several randomised controlled trials (RCTs) suggested that edaravone may be effective in treating ICH by improving the activities of daily living, as well as by not increasing mortality and incidence of adverse effects.

The common adverse effects associated with the use of edaravone include mild impairment of kidney and liver function, skin irritation and arrhythmia. Furthermore, edaravone is a relatively expensive drug, costing approximately US$600–860 for one standard course of treatment per stroke patient in China. It is worth noting that despite more than 200 trials have been reported in the last 8 years, the current status of edaravone as a therapeutic agent for ICH remains controversial, which warrants a systematic review and meta-analysis. Under these urgent circumstances, we decided to perform this updated systematic review and meta-analysis to obtain conclusive evidence in support of edaravone for ICH treatment.

### Objectives

This updated systematic review and meta-analysis aims at systematically analysing all of the RCTs to evaluate the efficacy and safety of edaravone for patients with acute ICH. Moreover, it aims to provide the best available evidence to enable both physicians and patients to make an informed choice regarding treatment for ICH.

### METHODS AND ANALYSIS

This protocol describes the procedure for a systematic review and meta-analysis of RCTs that reported the use of edaravone for the treatment of ICH. This protocol was performed following the reporting items listed in the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols, which was established to facilitate the preparation and reporting of a robust protocol for a systematic review and meta-analysis. The anticipated start date of this study is 23 April 2020.

### Eligibility criteria

1. **Types of studies**
   - RCTs with or without blinding will be included in this study. Non-RCTs, studies with the cross-over design, and uncontrolled clinical trials will be excluded.
2. **Types of participants**
   - Adult patients with acute ICH (within seven days) confirmed by CT or MRI according to a guideline for healthcare professionals from the American Heart Association/American Stroke Association will be included. There will be no restrictions in terms of the patients’ age, gender, race, education or economic status. Patients with traumatic haemorrhagic stroke, primary intraventricular haemorrhage and subarachnoid haemorrhage will be excluded.
3. **Types of intervention**
   - We will mainly focus on the intervention that edaravone was compared with the placebo or no treatment. Additionally, trials wherein routine treatments or cointerventions with edaravone were administered equally to all groups will also be included. However, there will be no restriction on the course of treatment.
4. **Types of outcome measures**
   - As ICH is a life-threatening condition with a high rate of disability, we will pay more attention to mortality and the long-term functional status in this systematic review. Clinical studies that reported numerical data on one or more of the following outcomes will be considered:
     1. **Primary outcomes**
        - All-cause mortality and dependency at the end of the follow-up will be set as the primary outcomes. The functional status was assessed using clinical scales including the modified Rankin Scale (mRS), Glasgow Outcome Scale (GOS) and Barthel Index (BI). The dependency will be defined as mRS grades 3–6, GOS grades 1–3, or BI less than or equal to 60.
      2. **Secondary outcomes**
The secondary outcomes will include: (1) improvement of neurological impairment assessed using clinical scales including the National Institute of Health Stroke Scale, Canadian Neurological Scale, European Stroke Scale, Scandinavian Stroke Scale, Modified Edinburgh-Scandinavian Stroke Scale and other related scales, (2) the total efficiency rate including cure rate, obvious effective rate and effective rate, and (3) reduction in the haematoma volume.

3. Safety outcome
Adverse effects of edaravone including impairment of kidney and liver function, skin irritation, nausea, will be evaluated.

Search strategy
We will conduct the comprehensive electronic searches of Medline, Embase and Cochrane Central Register of Controlled Trials. Given that edaravone is widely used in China, we will search the following Chinese databases: China National Knowledge Infrastructure, Chinese scientific periodical database of VIP INFORMATION, Wanfang Data and SinoMed from their respective inception dates to 23 April 2020. In addition, we will also search for clinical trial registers, dissertations and grey literature. We will develop the search strategy for Medline (see online supplementary appendix 1. Search Strategy Example) and the equivalent search words will be used in other databases as well. The registers which mainly include ongoing or unpublished trials are the following:

- WHO International Clinical Trials Registry Platform.
- ClinicalTrials.gov.
- The United Kingdoms’ ISRCTN registry (ISRCTN).
- Chinese Clinical Trial Registry.
- Australia and New Zealand Clinical Trials Registry.
- The Netherlands Trial Register.
- German Clinical Trials Register.
- Japan Primary Registries Network.
- Clinical Trials Registry—India.
- Iranian Registry of Clinical Trials.
- Sri Lanka Clinical Trials Registry.

Our research will be restricted to humans and clinical trials, with no language restrictions.

Screening and selection
Duplicate articles will be removed after identifying them by database searching. Two review authors (LF, TL) will independently screen the articles for titles and abstracts according to the inclusion criteria. The full text will be reviewed if necessary. In addition to this, the list of related studies from the references will be examined further to identify other potential studies to be included. The reviewers will exclude reports that are irrelevant to our research and retrieve full-text articles for the remaining references. The same two reviewers will independently screen these full-text articles to identify studies for inclusion, as well as determine and record reasons for the exclusion of ineligible studies. They will resolve any disagreements through discussion or, if required, they will consult a third review author (YG) to arbitrate when disagreements are not resolved. The excluded studies will be listed in a table with the proper reasons. The whole process of study screening and selection is shown in figure 1.

Data extraction
Two review authors (QY, PJ) will independently extract data on methods, patients, interventions, outcomes and results from the included studies, using a preformulated data collection form. We will try to contact the corresponding authors for any missing data or clarification on unclear information.

Quality assessment
The methodological quality assessment of the eligible studies will be independently conducted by two reviewers (LF, NL) for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions. Disagreements will be resolved by discussion or by involving another review author (YG). The risk of bias will be assessed according to the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting and other bias. The risk of bias for each domain will be classified into three levels: low risk, high risk and unclear. Unclear items in studies will be inquired by contacting the corresponding authors for details. We will provide information from the study report together with a justification for our judgement, in the ‘risk of bias’ tables.

Data synthesis and management
1. Measures of treatment effect
We plan to summarise the data using risk ratio calculations and 95% CIs for dichotomous outcomes and mean differences with 95% CIs for continuous outcomes in the final analysis. We will calculate standardised mean differences with 95% CIs when different scales were used to measure the same continuous outcome variable.

2. Dealing with missing data
The corresponding author will be contacted by reviewers via email or telephone to obtain the missing data or information which was not clearly described. In case the missing data are unavailable, intention-to-treat and sensitivity analyses will be performed to address the potential impact of the missing data, which will then be discussed if necessary.

3. Assessment of heterogeneity and data synthesis
Statistical heterogeneity among the included trials will be evaluated using the I² test. A meta-analysis will be conducted if there is no significant clinical (relating to the participants, interventions, controls and outcomes) and statistical heterogeneity (I² values are less than 75%) between the included trials. However, if the I² value is less than 25%, we will use a fixed-effect model to synthesise the data, and if it is between 25% and...
75%, we will estimate the sources of the heterogeneity.
If the statistical heterogeneity is explained successfully by sensitive analysis or subgroup analysis (ie, I² is less than 25%), we will also use the fixed-effect model to synthesise the data. Otherwise, a random-effect model will be applied. Data will not be synthesised if there is a significant level of statistical heterogeneity among the trials (ie, I² is greater than 75%) that cannot be explained or handled by subgroup analysis. All statistical analyses will be performed using Review Manager V.5.3 (The Cochrane Collaboration) software.

4. Analysis of subgroups or subsets
If the data are available for the subgroup analyses, we will plan to compare:
- Effects in patients with various dose of edaravone (less than 60 mg/day, 60 mg/day and more than 60 mg/day);
- Effects in patients with various course of treatment (less than 14 days, 14 days and more than 14 days);
- Effects in patients with various drug combinations (edaravone plus nimodipine, and edaravone plus other neuroprotective agents);
- Effects in patients with various types of ICH based on Structural lesion, Medication, Amyloid angiopathy, Systemic/other disease, Hypertension, Undetermined aetiological classification;
- Effects in patients with various course of disease (within 24 hours and after 24 hours from stroke onset);
- Effects in patients with various haemorrhage sites (brain stem, cerebellum, basal ganglia region and other sites).

5. Assessment of reporting biases
A funnel plot will be generated to explore the possibility of publication bias if 10 or more trials are included per comparison.

Confidence in cumulative evidence
The strength of the body of evidence in this review will be categorised as high, moderate, low or very low according to the Grading of Recommendations Assessment, Development and Evaluation system using the GRADEpro software.

Patient and public involvement
Not applicable. This protocol of systematic review and meta-analysis does not directly involve patients and the general public. Data will be collected from published articles retrieved from main databases and manual search.

Figure 1 Flow diagram of the study selection process. ICH, intracerebral haemorrhage.
The long-term clinical outcomes of edaravone therapy remain unclear despite its benefits in the basic management of ICH. Neuroprotective agents developed based on the specific pathological mechanism are potentially beneficial for ICH treatment. Edaravone is widely used in China, and is even mentioned in the Chinese guidelines for acute ICH management. Previous meta-analyses have shown edaravone to be effective only in improving neurological impairment for patients with ICH. Free radical injury is involved in the pathological process of both ICH and AIS, though it may be induced at different timepoints in the two conditions. Edaravone acting as a free radical scavenger is effective for AIS when administered during a specific time window. Therefore, the optimal time for initiating the edaravone treatment, the proper dose and duration of treatment for ICH deserve to be studied in depth. Besides, improvement of neurological deficits is the surrogate outcome when it comes to the assessment of specific treatment for stroke, and lacks robust support strength. Mortality and functional status after the long-term follow-up measured with mRS, GOS and BI should be the most important outcomes when evaluating the treatment efficacy of new therapeutic agents. However, previous meta-analyses do not address these issues due to the lack of reports in the previously included articles. After adding new clinical reports to this updated systematic review and meta-analysis, we will mainly focus on long-term functional status and mortality as primary outcomes for the evaluation of edaravone.

This protocol has some potential limitations. Various timepoints, dose and duration of edaravone usage in clinical trials may lead to heterogeneous findings. As different scales were used for outcome assessment, it may be impossible to perform a pooled analysis of all included studies. Subgroup analyses, however, will be performed according to the different therapeutic schedules and different outcomes measurements if data are available. Additionally, we will interpret the results with caution and take a critical approach when assessing the overall evidence.

In conclusion, the systematic review and meta-analysis we proposed will help update the existing evidence on the benefits and harms of edaravone treatment for ICH, thereby enabling patients, research fellows and clinical physicians to make the proper choice regarding treatment for ICH.

Acknowledgements The authors would like to thank Editage (www.editage.com) for English language editing.

Contributors YG put forward the conception of the study. LF and NL designed the study. LF drafted the protocol and then it was revised by NL, SG, CZ and YG. LF and TL will independently screen the potential studies, and then LF and NL will independently assess the risk of bias of the included studies. YG will arbitrate any disagreements during the review. QY and PJ will extract data. LF will perform data synthesis. All authors have read and approved the final submitted version of this protocol.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs Luda Feng http://orcid.org/0000-0002-7259-4421 Ying Gao http://orcid.org/0000-0001-6972-3846

REFERENCES
1 van Asch CJ, Luitse MJ, Rinkel GJ, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010;9:167–76.
2 Wu S, Wu B, Liu M, et al. Stroke in China: advances and challenges in epidemiology, prevention, and management. Lancet Neurol 2019;18:394–405.
3 Tsai C-F, Thomas B, Sudlow CML. Epidemiology of stroke and its subtypes in Chinese and white populations: a systematic review. Neurology 2013;81:264–72.
4 Qureshi AI, Tuhrim S, Broderick JP, et al. Spontaneous intracerebral hemorrhage. N Engl J Med 2001;344:1450–60.
5 Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet 2009;373:1632–44.
6 Cordonnier C, Demchuk A, Ziai W, et al. Intracerebral haemorrhage: current approaches to acute management. Lancet 2018;392:1257–68.
7 Keep RF, Hua Y, Xi G. Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. Lancet Neurol 2012;11:720–31.
8 An SJ, Kim TJ, Yoon B-W. Epidemiology, risk factors, and clinical features of intracerebral hemorrhage: an update. J Stroke 2017;19:3–10.
9 Hemphill JC; Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American heart association/ American stroke association. Stroke 2015;46:2032–60.
10 Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral hemorrhage. Lancet Neurol 2006;5:53–63.
11 Lyden PD, Shuaib A, Lees KR, et al. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT trial. Stroke 2007;38:2262–9.
12 Liu H, Uno M, Kitazato KT, et al. Peripheral oxidative biomarkers constitute a valuable indicator of the severity of oxidative brain damage in acute cerebral infarction. Brain Res 2004;1025:43–50.
13 Abe K, Yuki S, Kogure K. Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke 1988;19:460–5.
14 Watanabe T, Yuki S, Egawa M, et al. Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther 1994;268:657–604.
15 Muzuno A, Umemura K, Nakashima M. Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischemia following rat middle cerebral artery occlusion. Gen Pharmacol 1998;30:573–8.
16 Uno M, Kitazato KT, Suzue A, et al. Inhibition of brain damage by edaravone, a free radical scavenger, can be monitored by plasma biomarkers that detect oxidative and astrocyte damage in patients with acute cerebral infarction. Free Radic Biol Med 2005;38:1109–16.
17 Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Cerebrovasc Dis 2003;15:222–9.
18 Shinohara Y, Yanagihara T, Abe K, et al. Cerebral Infarction/Transient ischemic attack (TIA). J Stroke Cerebrovasc 2011;20:531–73.
19 Nakamura T, Kuroda Y, Yamashita S, et al. Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage. Stroke 2008;39:463–9.
20 Wang H, Cui D, Yang D, et al. The radical scavenger edaravone improves neurologic function and perihematoma glucose metabolism after acute intracerebral hemorrhage. J Stroke Cerebrovasc Dis 2015;24:215–22.
21 Zhang Y, Yang Y, Zhang GZ, et al. Stereotactic administration of edaravone ameliorates collagenase-induced intracerebral hemorrhage in rat. CNS Neurosci Ther 2016;22:824–35.
22 Yoshida H, Yanai H, Namiki Y, et al. Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev 2006;12:9–20.
23 Lu L, Sun X, Zhang J, et al. Study of free radical scavenger for the treatment of acute intracerebral hemorrhage. Chin J Crit Care Med 2007;448–51.
24 Zhang N, Komine-Kobayashi M, Tanaka R, et al. Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 2005;36:2220–5.
25 Yamashita T, Kamiya T, Deguchi K, et al. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab 2009;29:715–25.
26 Yang J, Liu M, Zhou J, et al. Edaravone for acute intracerebral haemorrhage. Cochrane Database Syst Rev 2011;CD007755.
27 Yang J, Cui X, Li J, et al. Edaravone for acute stroke: meta-analyses of data from randomized controlled trials. Dev Neurorehabil 2015;18:330–5.
28 Liu Y, Xie X, Yang H. Clinical effect of nimodipine combined with brain protective agent on hypertensive cerebral hemorrhage. Clin Res Pr 2019;4:51–2.
29 Ze Y. Clinical effect observation of edaravone in the treatment of 60 cases of acute cerebral hemorrhage. Chin Community Doc 2015;31:86–7.
30 Dai D. Free radical scavenger edaravone in the treatment of acute cerebral hemorrhage. China Health Vis 2013;21:533–4.
31 Xu M, Zhang W, Wang L, et al. The effect and safety of acupuncture on patients with functional constipation. Medicine 2019;98:e18125.
32 Wu H, Su G, Zhao Z. Adverse reactions of edaravone: a retrospective analysis. J Aoplexy Nerv Dis 2008;25:758–7.
33 Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
34 Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.
35 Higgins JPT. Cochrane Handbook for systematic reviews of interventions version 6.0. 2nd edn. Chichester (UK: John Wiley & Sons, 2019).
36 Abraha I, Cozzolino F, Orso M, et al. A systematic review found that deviations from intention-to-treat are common in randomized trials and systematic reviews. J Clin Epidemiol 2011;64:1105–13.
37 Porta N, Bonet C, Cobo E. Discordance between reported intention-to-treat and per protocol analyses. J Clin Epidemiol 2007;60:663–9.
38 Guyatt GH, Oxman AD, Vist GE, et al. Grade: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:344–9.
39 Neurology CSO, Society CS. Chinese guidelines for diagnosis and treatment of acute intracerebral hemorrhage 2019. Chin J Neurol 2019;52:994–1005.